SCHEMBL2246971

SCHEMBL2246971

COc1ccc2ncc([N+](=O)[O-])c(Nc3ccccc3Cl)c2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
MAPK1 P28482 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
SRC P12931 3/20 0.51
CSF1R P07333 1/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
PIN1 Q13526 1/20 0.43
AKR1B10 O60218 1/20 0.43
AKR1B1 P15121 1/20 0.43
AKR1C4 P17516 1/20 0.43
AKR1C1 Q04828 1/20 0.43
THRB P10828 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2249684 0.83 MAPK1 (0.56) ALDH1A1MAPK1LMNAHTTCSF1R
SCHEMBL2246108 0.81 SRC (0.55) SRCCSF1RMAPTABL1BCR
SCHEMBL28826676 0.79 CSF1R (0.56) ALDH1A1MAPK1LMNAHTTSRC
SCHEMBL2246795 0.79 PIN1 (0.49) ALDH1A1MAPK1LMNAHTTMAPT
SCHEMBL358801 0.78 NPC1 (0.59) ALDH1A1MAPK1HTTSRCMAPT
SCHEMBL29207216 0.75 GAA (0.47) ALDH1A1MAPK1HTTCSF1RMAPT
SCHEMBL30849463 0.75 GAA (0.47) ALDH1A1MAPK1HTTCSF1RMAPT
SCHEMBL2068067 0.74 MAPK1 (0.42) ALDH1A1MAPK1MAPTABL1
SCHEMBL2246907 0.74 LMNA (0.45) ALDH1A1MAPK1LMNAHTTMAPT
SCHEMBL7878714 0.74 MAPK1 (0.42) ALDH1A1MAPK1LMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 US disclosed
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 US disclosed
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 US disclosed
EP-1509521-B1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2008-08-20 EP disclosed
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-11-03 US disclosed
EP-1509521-A2 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-02 EP disclosed
WO-2003097641-A2 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases ABL1, PRKCA, PRKCQ ALDH1A1 3073/4885MAPK1 251/4885LMNA 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.